Health news
To ensure the availability of the life saving drug, Peramivir IV, to the countries of the Middle East and North Africa (MENA) region, Hikma Pharmaceuticals signed an agreement with BioCryst Pharmaceuticals to manage the pandemic H1N1 influenza.
Peramivir (an investigational drug on phase III clinical trials) is a potent, intravenously administered anti-viral agent that rapidly delivers high plasma concentrations to the sites of infection....